Efficacy and Safety of Yinzhihuang Granule Combined with Phototherapy in Neonatal Pathological Jaundice Treatment: A Meta-Analysis

NA ZHENG SHEN, D. WANG¹ AND L. FAN*

Department of Pediatrics, Institute of Chinese Medical Literature and Culture, ¹College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China

Shen et al.: Efficacy of Yinzhihuang Granule Combined with Phototherapy

To assess the efficacy and safety of Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice treatment. By searching China network knowledge infrastructure, Wan Fang database, Virtual IP address database, Virtual IP, PubMed, EmBase together with the Cochrane library until March 31st, 2022. Literatures on Yinzhihuang combined with phototherapy in neonatal pathological jaundice treatment were collected. Literatures were screened by the inclusion and exclusion criteria and data were extracted. A total of 19 literatures were included in this study, a total of 2221 neonates with pathological jaundice. The outcomes of meta-analysis demonstrated the total clinical effective rate of Yinzhihuang combined with phototherapy in neonatal pathological jaundice treatment was significantly higher than that of phototherapy group. The recovery time and hospital stay were shorter than those in the phototherapy group. The occurrence rate of adverse reactions was reduced compared to that of phototherapy group and the difference was significant. Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice treatment has better clinical effect and safety.

Key words: Yinzhhuang, pathological jaundice, phototherapy, curative effect, bilirubin

Neonatal jaundice refers to the aberrant metabolism of bilirubin and the clinical manifestations are yellow staining of skin, mucosa and even sclera caused by the elevated level of bilirubin in blood. It can be divided into pathological jaundice and physiological jaundice. It is one of the common pediatric diseases. In recent years, its incidence is increasing year by year^[1]. Excessive bilirubin in the neonatal period can cause brain neuropathy (namely bilirubin encephalopathy), which is manifested as not eating, not drinking and not making any disturbance. It is the most serious complication of pathological jaundice in the newborn, with serious condition and high mortality and permanent nerve damage can be caused to the nerves^[2]. The incidence of pathological jaundice in neonates is high in China. It is important to detect and effectively judge the nature of jaundice in time, diagnose and treat early, and prevent the occurrence of bilirubin encephalopathy. At present, the treatment of pathologic jaundice includes phototherapy, drug therapy and supportive therapy. Phototherapy is a common clinical treatment, including intermittent and continuous blue light irradiation. The treatment of drugs usually include probiotics (Mamaiai, Peifeikang, etc.), glucose powder, Yinzhihuang granule, which is the first choice for neonatal pathological jaundice treatment. Yinzhihuang granule is a preparation made of extracts of 4 kinds of traditional Chinese medicine, namely Artemisia, Gardenia, honeysuckle and Scutellaria. It has the effects of detoxification, dampness, heat clearing and allopathy. It is often used in the treatment of liver diseases in clinic and has been frequently used in neonatal pathological jaundice treatment in the last few years^[3-5]. Yinzhihuang granule by regulating bilirubin metabolism reduces the absorption of bilirubin, reduce the occurrence rate of adverse drug reactions and shorten the treatment time. In recent years, a number of literatures have compared the efficacy and safety of Yinzhihuang combined with phototherapy and phototherapy in neonatal pathological jaundice therapy^[6-24]. This study intended to collect domestic and foreign published studies on the efficacy and/or safety of Yinzhihuang combined with phototherapy and phototherapy in neonatal jaundice therapy and conducted a meta-analysis to assess the clinical efficacy and safety of Yinzhihuang combined phototherapy.

MATERIALS AND METHODS

Inclusion criteria:

The clinical Randomized Controlled Trials (RCTs) of Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice treatment were published at home and abroad. The study subjects met the diagnostic criteria of pathological jaundice in practical pediatrics at the age of 4 w after birth.

Intervention measures: The experimental group was treated with oral Yinzhihuang granules+phototherapy (blue light irradiation therapy), the control group was only treated with phototherapy, allowing patients to take symptomatic treatment when necessary (prevention of infection, relief of diarrhea, nutritional supplementation, etc.,).

Outcome index: The primary outcome index was clinical efficacy, which was determined according to the level of serum total bilirubin. Including four grades cure, special effect, effective and ineffective. Secondary outcome measures included direct bilirubin, indirect bilirubin, recovery time (defined as the time from onset to resolution of jaundice) and adverse drug reactions. Among them, the clinical effect was determined according to the clinical efficacy judgment standard of neonatal pathological jaundice in pediatrics.

The total effective rate=Significant efficiency+effective rate

Exclusion criteria:

The subjects had physiologic jaundice, hepatobiliary diseases or other hereditary diseases; non-randomized, non-clinical studies, retrospective studies, repeated literature, conference abstracts, reviews, individual cases, review literature; poorly designed studies with no outcome measures, incomplete and/or extractable outcome data, no control group, non-Chinese and English literature.

Search strategy:

China Network Knowledge Infrastructure (CNKI), Wan fang Data, Virtual IP Address, PubMed, Embase and Cochrane Library databases were searched to collect RCTs of Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice therapy. The search time limit was from March 31st, 2022. The search method of combining subject words and free words was used. The search words were Yinzhihuang granule, jaundice and the English search words were Yinzhihuang, jaundice and so on.

Literature selection and data extraction:

Two researchers screened the literature based on the inclusion and exclusion criteria, extracted data, discussed and decided by a third party in case of disagreement. End note X7 was used for literature screening to eliminate duplicate documents and irrelevant literature was excluded by reading the title and abstract. Finally, the full text was read to determine the included literature based on the inclusion criteria and exclusion criteria. The included literature was read through and extracted; title, author name, published literature, sample size and baseline data (age, gender, etc.,) of the experimental group and the control group, study type and intervention measures and outcome indicators.

Literature quality evaluation:

By Cochrane RevMan5.3 software risk bias tool for quality evaluation into the literature including seven items. The generation of random sequence and allocation concealment (perpetrators and participants), double blind and ending index evaluation personnel blinded, incomplete data, publication bias, other bias, each project bias risk include: low risk, uncertain and high risk.

Statistical analysis:

RevMan5.3 software was used for meta-analysis. Relative Risk (RR) was used for enumeration data and Standard Mean Difference (SMD) was used for measurement data. When I2 \leq 50 %, p>0.05, the possibility of heterogeneity was small and the fixed effect model was used. When I2>50 % and p \leq 0.05, heterogeneity was indicated and subgroup analysis or random effect model analysis was used. The pooled statistic was p<0.05 to indicate statistical significance.

RESULTS AND DISSCUSION

As displayed in fig. 1, a total of 886 articles were included in the primary selection, containing 189 articles from CNKI, 404 articles from Wan fang, 216 articles from VIP, 7 articles from PubMed, 2 articles from Embase and 68 articles from Cochrane Library. Based on the inclusion criteria, the most popular 19 articles were included in the meta-analysis *via* reading the title, abstract and full text. The basic information of the included literature was indicated in Table 1.



Fig. 1: Literature screening process

TABLE 1: BASIC INFORMATION OF THE INCLUDED LITERATURE

Included	Sample (male/f	e size emale)	Average	age (day)	Intervening m	Yin Zhihuang	Course of treatment	Outcome	
studies	Т	С	Т	С	т	С	dose	(Day)	Indicator
Fengmin et al. ^[6]	23/16	21/18	10.43±3.86	10.15±3.69	Yinzhihuang granules+intermittent blue light irradiation+live binary Bacillus subtilis	Intermittent blue light irradiation+live binary Bacillus subtilis	3 g/d	5	(1) (2) (4)
Li et al. ^[7]	46/29	48/27	5.32±1.35	5.28±1.34	Yinzhihuang granule+intermittent blue light irradiation	Intermittent blue light irradiation	3 g/d	7	(1) (2) (5) (7)
Hongguang et al. ^[8]	24/18	23/19	10.69±1.63	10.74±1.85	Yinzhihuang granule+blue light irradiation+ Saccharomyces boulardii sachets	Blue light irradiation+ Saccharomyces boulardii sachets	3 g/d	5	(1) (4) (5)
Li et al. ^[9]	29/16	28/17	15.21±2.11	15.28±2.12	Yinzhihuang granule+ single blue light irradiation	Single blue light irradiation	7.5 ml/d	7	(1) (2) (4) (5) (7)
Chen <i>et</i> al. ^[10]	16/14	17/13	8.1±1.6	7.5±13	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	NA	7	(1) (5)
Zhou et al. ^[11]	NA	NA	NA	NA	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	3 g/d	6	(1) (2)
Bai <i>et</i> al. ^[12]	23/19	25/17	8.1±3.2	8.5±3.4	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	3 g/d	5	(1) (4) (7)
Xiufang et al. ^[13]	48/25	47/27	5.31±1.02	5.11±1.03	Yinzhihuang granule+ intermittent blue light irradiation	Intermittent blue light irradiation	3 g/d	7	(1) (2) (6)(7)
Juan <i>et al</i> . ^[14]	40/35	39/36	NA	NA	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	3 g/d	5	(1) (2) (4) (7)
Deyong et al. ^[15]	19/17	17/19	NA	NA	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	4.5 g/d	7	(1) (6) (7)
Ying et al. ^[16]	31/24	32/23	7.11±1.16	7.01±1.12	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	NA	6	(1) (2) (6)
Fang et al. ^[17]	32/28	32/28	5. 4±0. 9	6. 2±0. 7	Yinzhihuang granule+ blue light irradiation	Blue light irradiation	3 g/d	7	(1) (2) (4)

www.ijpsonline.com

Yan <i>et</i> al. ^[18]	26/24	27/23	17.25±2.03	17.30±0.08	Yinzhihuang granule+blue light irradiation	Blue light irradiation	3 g/d	7	(1) (6) (7)
Huanan et al. ^[19]	28/13	23/18	15.13±6.87	15.41±6.91	Yinzhihuang granule+intermittent blue light irradiation	Intermittent blue light irradiation	3 g/d	7	(1) (2) (4) (5)
Xiaoli et al. ^[20]	31/15	29/17	7.0±2.3	7.2±2.5	Yinzhihuang granule+blue light irradiation	Blue light irradiation	3 g/d	7	(1) (3) (4) (6) (7)
Li <i>et al.</i> ^[21]	101/86	116/71	4.30±1.46	4.22±1.49	Yinzhihuang granule+pure blue light irradiation	Pure blue light irradiation	3 g/d	7	(1) (3) (4) (7)
Shan et al. ^[22]	37/28	38/27	14.2±2.0	14.2±1.9	Yinzhihuang granule+pure blue light irradiation	Pure blue light irradiation	3 g/d	7	(1) (2) (4)
Qibing et al. ^[23]	26/24	27/23	14.2±2.9	13.9±2.8	Yinzhihuang granule+pure blue light irradiation	Pure blue light irradiation	3 g/d	7	(1) (2) (7)
Jingli et al. ^[24]	29/20	31/18	10.63±5.17	10.85±5.31	Yinzhihuang granule+pure blue light irradiation	Pure blue light irradiation	3 g/d	7	(1) (2) (3) (7)

Note: (1): Clinical efficacy; (2): Bilirubin; (3): Total bile acids; (4): Recovery time; (5): Length of hospital stay; (6): Company with other and (7): Adverse reactions

The 19 included literatures all mentioned the specific method of randomization, complete outcome data and no selective reporting. No literatures mentioned the allocation hiding and whether it was double-blind (implementer and participant). The 3 literatures did not mention whether the outcome indicator evaluation was blinded, as shown in fig. 2.

A total of 16 studies were included, and the heterogeneity test showed that there was no significant heterogeneity among the studies (χ^2 =17.39, p=0.30, I2=14 %). The fixed-effect model was utilized for analysis and the results were shown in fig. 3. The results unveiled a significant difference in the total effective rate between the two groups (RR=1.22, 95 % CI=(1.18,1.26), p<0.00001). The total effective rate of Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice therapy was significantly higher than that of phototherapy.

A total of 16 studies were included and the heterogeneity test manifested a significant heterogeneity among the studies (χ^2 =109.35, p<0.00001, I2=99 %). The random effect model was adopted to analyze the results, as indicated in fig. 4. The results demonstrated that the difference of serum total bilirubin level between the two groups was significant (SMD=-32.76, 95 % CI=(-38.30, -27.23), p<0.00001). The serum total bilirubin level of Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice treatment was lower than that of phototherapy.

A total of 10 studies were included and the heterogeneity test showed a significant heterogeneity among the studies (χ^2 =139.78, p<0.00001, I2=94 %). The random effects model was utilized to analyze the results, as shown in fig. 5. The results displayed that the difference of recovery time between the two groups was significant (SMD=-1.45, 95 % CI=(-2.01, -0.89), p<0.00001). Yinzhihuang granule combined with phototherapy in the treatment of neonatal pathological jaundice had a shorter recovery time than phototherapy. A total of 5 studies were included and the heterogeneity test showed that there was significant heterogeneity among the studies (χ^2 =25.54, p<0.0001, I2=84 %). The random effect model was used for analysis and the results were shown in fig. 6. The analysis results showed that the difference of hospital stay between the two groups was statistically significant (SMD=-3.55, 95 % CI=(-4.65,-2.46), p<0.00001). Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice treatment had a shorter hospital stay than phototherapy.

A total of 9 studies were included and the heterogeneity test exhibited a significant heterogeneity among the studies (χ^2 =18.89, p=0.02, I2=58 %). The random effect model was adopted to analyze the results, as shown in fig. 7. The outcomes uncovered a significant difference in the occurrence rate of adverse reactions between the two groups (RR=0.53, 95 % CI=(0.30, 0.93), p=0.03). The occurrence rate of adverse reactions of Yinzhihuang granule combined with phototherapy in neonatal pathological jaundice treatment was lower

than that of phototherapy.

The funnel plot was drawn with the five outcome indicators of total clinical response rate, total serum bilirubin, recovery time, length of hospital stay, as well as adverse drug reactions, as shown in fig. 8. The results showed that the included literatures of total clinical response rate, recovery time and length of hospital stay were basically symmetrically distributed in the funnel plot, and the possibility of publication bias was small. The three items of serum total bilirubin and adverse drug reactions were not symmetrically distributed in the funnel plot, suggesting that there may be a large publication bias.



Fig. 2: Results of risk bias assessment Note: (■): Low risk of bias; (■): Unclear risk of bias and (■): High risk of bias

tudy or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-1	I, Fixed, 95% Cl		
He 2017	51	55	39	55	4.9%	1.31 [1.09, 1.57]			+		
Feng 2017	69	73	53	74	6.7%	1.32 [1.13, 1.54]			+		
Liu 2016	64	65	57	65	7.2%	1.12 [1.02, 1.24]			-		
Zhou 2017	49	50	41	50	5.2%	1.20 [1.04, 1.37]			+		
Tang 2018	47	49	39	49	4.9%	1.21 [1.03, 1.40]			-		
Li 2020	183	187	163	187	20.7%	1.12 [1.06, 1.19]			-		
Li 2015	71	75	54	75	6.8%	1.31 [1.13, 1.53]			-		
Li 2019	43	45	31	45	3.9%	1.39 [1.13, 1.70]			-		
Du 2018	75	75	60	75	7.7%	1.25 [1.11, 1.40]			+		
Yang 2018	36	39	29	39	3.7%	1.24 [1.01, 1.52]					
Lin 2016	55	60	42	60	5.3%	1.31 [1.09, 1.57]			-		
Bai 2017	41	42	35	42	4.4%	1.17 [1.02, 1.35]			-		
Zheng 2019	39	41	33	41	4.2%	1.18 [1.00, 1.40]			+		
Chen 2017	48	50	42	50	5.3%	1.14 [1.00, 1.31]			-		
Ma2019	49	50	38	50	4.8%	1.29 [1.10, 1.51]			-		
Ma 2016	42	46	33	46	4.2%	1.27 [1.04, 1.56]			-		
Total (95% Cl)		1002		1003	100.0 %	1.22 [1.18, 1.26]			1		
Total events	962		789								
Heterogeneity: Chi ² = 1	17.39, df = 16	5 (P = 0.3	0); l ² = 14	1%						40	- 400
Test for overall effect: 2	Z = 11.32 (P	< 0.0000	1)				0.01	0.1	1	10	100

Fig. 3: Meta-analysis forest plot of clinical total effective rate analysis

		Expe	rimenta	al	с	ontrol			Mean Difference	Mean Difference
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
	He 2017	37.95	5.25	55	58.2	7.37	55	7.2%	-20.25 [-22.64, -17.86]	+
	Feng 2017	116.9	19.7	73	146.7	21.4	74	6.6%	-29.80 [-36.45, -23.15]	
	Liu 2016	108.12	9.13	65	153.02	11.24	65	7.1%	-44.90 [-48.42, -41.38]	+
	Zhou 2017	26.3	15.4	50	92.7	14.6	50	6.7%	-66.40 [-72.28, -60.52]	
	Tang 2018	19.75	1.74	49	41.48	1.99	49	7.3%	-21.73 [-22.47, -20.99]	•
	Li 2020	61.27	2.04	187	72.63	1.82	187	7.3%	-11.36 [-11.75, -10.97]	•
	Li 2015	81.54	15.38	75	113.65	19.52	75	6.8%	-32.11 [-37.73, -26.49]	
	Li 2019	225.54	83.53	45	267.24	95.53	45	1.7%	-41.70 [-78.78, -4.62]	
	Du 2018	79.1	17.6	75	126.3	22.9	75	6.6%	-47.20 [-53.74, -40.66]	
	Yang 2018	94.27	16.3	39	110.27	21.1	39	6.2%	-16.00 [-24.37, -7.63]	
l	Lin 2016	80	15	60	113	18	60	6.7%	-33.00 [-38.93, -27.07]	
	Bai 2017	106.49	25.03	60	144.32	31.18	60	5.9%	-37.83 [-47.95, -27.71]	
	Zheng 2019	96.32	8.34	41	114.29	13.13	41	6.9%	-17.97 [-22.73, -13.21]	
	Chen 2017	81.4	15.6	30	92.6	19.3	30	6.1%	-11.20 [-20.08, -2.32]	
	Ma2019	128	43.7	50	192.9	41.1	50	4.4%	-64.90 [-81.53, -48.27]	
	Ma 2016	105.42	14.63	46	152.77	21.26	46	6.4%	-47.35 [-54.81, -39.89]	
										•
	Total (95% CI)			1000			1001	100. 0%	-32.76 [-38.30, -27.23]	
	Heterogeneity: Tau² =	: 109.35; (Chi ² = 1	547.08	, df = 15 ((P < 0.0	0001);1	²= 99%		
	Test for overall effect:	Z = 11.60) (P < 0.)	00001)						-100 -30 0 30 100

Fig. 4: Forest plot of meta-analysis of total bilirubin levels after 1 course of treatment

		Exp	eriment	al	0	Control			Std. Mean Difference	Std.	Mean Differen	ice	
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV,	Random, 95%	CI	
	Liu 2016	4.8	1.2	65	8	2	65	11.1%	-1.93 [-2.35, -1.51]		-		
	Li 2020	5.39	0.56	187	7.98	1.14	187	11.5%	-2.88 [-3.17, -2.59]		-		
	Li 2015	5.58	2.16	75	10.82	3.54	75	11.2%	-1.78 [-2.16, -1.40]		-		
	Li 2019	5.2	1.7	75	7.7	1.9	75	11.3%	-1.38 [-1.74, -1.02]		-		
1	Du 2018	3.86	0.39	39	4.21	0.51	39	11.0%	-0.76 [-1.22, -0.30]		1		
	Yang 2018	6.95	2.01	0	9.42	2.53	0		Not estimable				
	Wang 2016	10.22	1.57	42	13.4	2.11	42	10.8%	-1.69 [-2.20, -1.19]		-		
	Bai 2017	4.91	1.98	41	7.51	2.46	41	10.9%	-1.15 [-1.62, -0.68]		-		
	Zheng 2019	9.13	12.41	45	12.13	11.24	45	11.1%	-0.25 [-0.67, 0.16]		1		
	Ma 2016	4.3	1.5	46	6.8	2.6	46	11.0%	-1.17 [-1.61, -0.72]		1		
	Total (95% CI)			615			615	100.0%	-1.45 [-2.01, -0.89]		1		
	Heterogeneity: Tau ² =	0.69; C	hi ² = 13	9.78, d	f= 8 (P	< 0.000	01); I ² =	94%		100 50	<u> </u>		- 100
	Test for overall effect	Z = 5.08	i(P < 0.	00001)						-100 -50	U	50	100

Fig. 5: Forest plot of recovery time meta-analysis

Experimental		ıtal	Control			Mean Difference			Mean Difference					
Study or St	ubgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV,	Random, 959	% CI	
Li 2015		7.28	3.24	75	12.64	4.58	75	18.3%	-5.36 [-6.63, -4.09]			•		
Li 2019		12.51	1.26	45	15.18	1.72	45	22.5%	-2.67 [-3.29, -2.05]			•		
Wang 201	6	7.38	1.95	42	10.86	2.82	42	19.9%	-3.48 [-4.52, -2.44]			-		
Zheng 20	19	8.97	2.31	41	10.86	3.23	41	18.7%	-1.89 [-3.11, -0.67]			-		
Chen 2017	7	5.57	1.46	30	10.06	2.16	30	20.6%	-4.49 [-5.42, -3.56]			•		
Total (95% Cl) 233 233 1 Heterogeneity: Tau ² = 1.30; Chi ² = 25.54, df = 4 (P < 0.0001); I ² = 8							233 01); I * =	100.0 % 84%	-3.55 [-4.65, -2.46]	-100	-50	-		100
Test for ove	erall effect: 2	Z = 6.34	(P < 0	0.00001	1)							5	50	100

Fig. 6: Forest plot of hospital stay meta-analysis

Experimental		ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Feng 2017	1	74	2	74	4.6%	0.50 [0.05, 5.40]	
Tang 2018	4	49	5	49	10.9%	0.80 [0.23, 2.80]	
Li 2020	25	187	58	187	20.5%	0.43 [0.28, 0.66]	
Du 2018	20	75	11	75	17.6%	1.82 [0.94, 3.53]	
Bai 2017	2	42	3	42	7.3%	0.67 [0.12, 3.79]	
Cheng 2019	2	36	13	36	9.5%	0.15 [0.04, 0.63]	
Chen 2017	2	50	5	51	8.2%	0.41 [0.08, 2.01]	
Ma2019	4	50	10	50	12.5%	0.40 [0.13, 1.19]	
Ma 2016	2	46	8	46	8.9%	0.25 [0.06, 1.11]	
Total (95% CI)		609		610	100.0%	0.53 [0.30, 0.93]	◆
Total events	62		115				
Heterogeneity: Tau ² =	0.36; Chi ^a	⁴ = 18.89	9, df = 8 (f	P = 0.0	2); I ² = 58	%	0.01 0.1 1 10 100
reactor overall effect.	z = 2.21 (r	- 0.03	<i>.</i>				

Fig. 7: Forest plot of meta-analysis of adverse drug reactions



Fig. 8: Funnel chart of 5 indicators

According to traditional Chinese medicine, the pathogenesis of pathological jaundice is cold and dampness block, dampness and heat stasis, and bile overflow, which is related to cold and dampness, and dampness and heat^[25]. Yinzhihuang granule comes from Yinchen Hao soup, 4 kinds of drugs synergistic effect, can get the effect of clearing heat and detoxifying, removing yellow and dampening, protecting liver and gallbladder. Yinzhihuang is used in the treatment of neonatal pathologic jaundice, but the sample size of the literature published in recent years is small. This study finally included 19 articles for research through screening, and the results showed that the treatment of Yinzhihuang combined with phototherapy in neonatal pathologic jaundice could effectively improve the clinical total effective rate, reduce serum total bilirubin level, shorten the recovery time and hospital stay. At the same time, the occurrence rate of adverse reactions was reduced and the safety was good.

Yinzhihuang granule has the function of protecting liver and gallbladder, by regulating Alanine Aminotransferase (ALT), total bile acid and other indicators, to achieve the role of regulating liver function. With the excretion of bilirubin in urine and feces, the jaundice is gradually subsided and the skin symptoms are improved. Some studies have shown that the main effects of Yinzhihuang granule can reduce bilirubin level^[26]. Compared with injection, oral administration not only avoids allergy, but also avoids invasive operation. Besides, its antibacterial effect is improved and the destruction of red blood cells is reduced when combined with antibiotics. Moreover, it can inhibit body allergy, reduce red blood cell hemolysis. Experimental studies in rats with hyperbilirubinemia have showed that Yinzhihuang granules inhibit the increase of bilirubin by elevating the expression of organic anion transport polypeptide 1b2, multidrug resistance associated protein 2 and Uridine Diphosphate (UDP)-glucuronosyltransferase 1A1^[27]. Some studies have shown that Yinzhihuang granule can promote the secretion and antagonism of bile, improve the levels of serum liver enzymes and accelerate the jaundice resolution time^[28]. It can effectively reduce the level of bilirubin, improve the clinical efficiency, as well as shorten the recovery time and hospital stay. Yinzhihuang combined with phototherapy in neonatal pathological jaundice treatment has a significant clinical effect. In terms of safety, combination therapy has a lower occurrence rate of adverse reactions. The side effects of phototherapy include fever, diarrhea, skin rash erythema, testicular

damage and dehydration, etc.,^[29] while the side effects of Yinzhihuang are often manifested as diarrhea and vomiting, especially in patients with spleen deficiency and loose stool^[30]. The above side effects are mild and can be relieved spontaneously after discontinuation of the drug. However, but the results of this study results indicated that Yinzhihuang combined with phototherapy treatment had lower occurrence rate of adverse reactions and better security^[1-19]. In this study, all the included literatures adopted clear randomization method and reported complete data without high risk bias. However, the literature included in this study did not mention whether it was double-blind or allocation hiding.

In conclusion, 19 literatures were included in this study to analyze the clinical effect and safety of Yinzhihuang combined phototherapy in the treatment of neonatal pathological jaundice. The results showed that Yinzhihuang combined phototherapy was better than phototherapy in the treatment of neonatal pathological jaundice and the safety was also better than phototherapy. However, there are some limitations in these studies, such as no blinded method, no further follow-up of children, single case source and no multicenter study, etc. The clinical effect and safety of Yinzhihuang combined phototherapy in neonatal pathological jaundice treatment need to be confirmed by clinical multicenter prospective studies.

Conflict of interests:

The authors declared no conflict of interests.

REFERENCES

- 1. Weixiu Y, Xuemei R, Bangsong J. Effects of infantile massage combined with Yinchenhao decoction combined with short-term and multiple blue light irradiation on liver function, myocardial enzyme spectrum and nerve function in neonatal jaundice children. Dietary Health 2021;33:88-89.
- Haina D, Yan C, Caijun Y. Effect of traditional Chinese medicine bath combined with blue light irradiation on neonatal jaundice. Chin Sci Technol Tradit Chin Med 2020;27(6):144-6.
- 3. Fang Z, Jiyuan C, Yu Z. Effect of Yinzhihuang oral liquid and mia combined with phototherapy on neonatal jaundice. Pharm Industry 2019;4:1.
- Huifang S, Yanlin L, Wei D. Comparison of two different feeding methods of Yinzhihuang oral liquid in the treatment of neonatal jaundice. Chin J Clin Pharmacol 2022;3:101-3.
- Caidie T, Jian L, Yanming X. Systematic review and meta-analysis of Yinzhihuang oral liquid in the treatment of neonatal jaundice. Chin J Tradit Chin Med 2019;24:10.
- 6. Fengmin Y. Clinical study of live *Bacillus subtilis* combined with Yinzhihuang granule in the treatment of neonatal hyperbilirubinemia. Mod Diag Ther 2018;24:2.
- Li J, Hu Y. Clinical study of blue light combined with Yinzhihuang granule in the treatment of neonatal pathological jaundice. Chin J Clin Pharmacol 2015;18:1809-11.

- Hongguang W. Blue light irradiation combined with Yinzhihuang granule and *Saccharomyces boulardii* powder in the treatment of neonatal jaundice efficacy observation. J Pregnancy 2020;2(5):76-7.
- 9. Li L. Effect of Yinzhihuang granule combined with blue light in the treatment of neonatal jaundice. Chin Med Guide 2019;17(18):2.
- Chen J, Yuan H, Chen Z. Efficacy evaluation of Yinzhihuang granules in adjuvant treatment of neonatal jaundice. Shenzhen J Integr Tradit Chin West Med 2017;27(10):32-3.
- 11. Zhou J. Clinical effect of Yinzhihuang granule combined with blue light irradiation on neonatal jaundice. World Clin Med 2017;11(4):1.
- 12. Bai C. Clinical analysis of Yinzhihuang granule combined with blue light in the treatment of 42 cases of neonatal jaundice. Health J 2017;12:137.
- 13. Xiufang F. Effect of Yinzhihuang granule combined with blue light on thyroid function, AFP and CRP in neonates with pathological jaundice. Chin Mat Child Health 2017;19.
- Juan D, Xiaoqin Z. Yinzhihuang granule in the treatment of neonatal pathological jaundice. Jilin Tradit Chin Med 2018;38(9):1046-9.
- Deyong C, Xiaoling D, Hao C. Clinical effect of Yinzhihuang granule in the treatment of neonatal jaundice. Chin J Biochem Drugs 2017;37(6):3.
- Ying H, Manhong C. Effects of Yinzhihuang granule combined with short-term multiple blue light irradiation on serum TBIL, ALT, AST in children with jaundice. Chin J Biochem Drugs 2017;37(12):2.
- 17. Fang L, Jie S. Comparison of curative effect between blue light therapy and compound Chinese medicine in the treatment of neonatal jaundice. Med Rev 2016;22(12):3.
- Yan M, Lan G, Li G. Efficacy and safety analysis of blue light irradiation combined with Yinzhihuang granule in the treatment of neonatal jaundice. World Tradit Chin Med 2019;14(12):4.
- 19. Huanan Z. Clinical study on Yinzhihuang granule combined with blue light intermittent irradiation in the treatment of neonatal pathological jaundice. New Chin Med 2019;8:3.
- Xiaoli M, Lianying L. Clinical study on Yinzhihuang granule combined with blue light irradiation in the treatment of dampheat furnigated neonatal jaundice. Liaoning J Tradit Chin Med 2016;43(2):3.

- 21. Li ZH, Xie CC, Tao DY. Clinical observation of Yinzhihuang granule in the treatment of neonatal pathological jaundice. Chin Pract Med 2020;15:14-6.
- 22. Shan L. Clinical efficacy of Yinzhihuang granule in the treatment of neonatal pathological jaundice. J Rational Clin Drug Use 2016;9(3):137-8.
- Qibing C, Jiandong C. Clinical efficacy and safety of Yinzhihuang granule in the treatment of neonatal pathological jaundice. J Rational Clin Drug Use 2017;10(23):2.
- 24. Jingli T, Xiaoping L, Shouqiong Z. Effect of Yinzhihuang combined with blue light irradiation on neonatal jaundice. Hainan Med J 2018;29(3):3.
- Aizhen W, Lijuan G, Huiling J. Effect of traditional Chinese medicine treatment and nursing measures on wet heat fumigated neonatal pathological jaundice. New Chin Med 2020;52(7):4.
- 26. Cai H. Effect analysis of Yinzhihuang oral liquid in treatment of cholestatic jaundice. J Clin Med 2020;7(96):1.
- 27. Jianlong L. Clinical study of Yinzhihuang Granule in the treatment of neonatal pathological jaundice. Shanxi Univ Tradit Chin Med 2015.
- Juanlei L, Songyan Y, Yaning Q. Effect of blue light irradiation combined with Yinzhihuang in the treatment of neonates with pathologic jaundice and its influence on bilirubin and total bile acids. Family Med 2020;2:50-4.
- Hongli C, Ting W. Clinical effect of Yinzhihuang oral liquid combined with blue light on neonatal hyperbilirubinemia. J Clin Med Res Pract 2020;5(7):3.
- Xiao F, Xiaomei D. Research progress on adverse effects of phototherapy in neonates with hyperbilirubinemia. J Clin Pediatr 2020;38(9):5.

This article was originally published in a special issue, "Current Trends in Pharmaceutical and Biomedical Sciences" Indian J Pharm Sci 2022:84(5) Spl Issue "278-285"

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms